• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

进一步研究 4-((((3S,6S)-6-(苯并[d][1,3]二氧戊环-5-基)四氢-2H-吡喃-3-基)氨基)甲基)苯酚的构效关系:鉴定具有三重摄取抑制活性的化合物作为潜在的抗抑郁药。

Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.

机构信息

Department of Pharmaceutical Sciences, Wayne State University, Detroit, Michigan 48202, United States.

出版信息

J Med Chem. 2011 Apr 28;54(8):2924-32. doi: 10.1021/jm200020a. Epub 2011 Mar 29.

DOI:10.1021/jm200020a
PMID:21446715
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3085959/
Abstract

To investigate structural alterations of the lead triple uptake inhibitor molecule, disubstituted 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol, we have carried out structure-activity relationship (SAR) studies to investigate the effect of alteration of aromatic substitutions and introduction of heterocyclic aromatic moieties on this molecular template. The novel compounds were tested for their affinities for the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) in the brain by measuring their potency in inhibiting the uptake of [(3)H]DA, [(3)H]5-HT, and [(3)H]NE, respectively. SAR results indicate dopamine norepinephrine reuptake inhibitory (DNRI) type activity in thiophene (10g) and pyrrole (10i) derivatives. On the other hand, 3-hydroxyphenyl derivative 10f and 4-methoxyphenyl derivative 10j exhibited a triple reuptake inhibitory (TUI) activity profile, as these molecules exhibited potent uptake inhibition for all the monoamine transporters (K(i) of 31.3, 40, 38.5 and K(i) of 15.9, 12.9, 29.3 for DAT, SERT, and NET for 10f and 10g, respectively). Compound 10f was further evaluated in the rat forced swim test to evaluate its potential antidepressant effect. The results show significant reduction of immobility by TUI 10f at 10 mg/kg dose, indicating potential antidepressant activity.

摘要

为了研究铅三重摄取抑制剂分子、取代的 4-(((3S,6S)-6-苄基四氢-2H-吡喃-3-基)氨基)甲基)苯酚的结构变化,我们进行了构效关系(SAR)研究,以研究改变芳香取代基和引入杂环芳香部分对该分子模板的影响。通过测量它们抑制[(3)H]DA、[(3)H]5-HT 和 [(3)H]NE 摄取的能力,测试了这些新型化合物对多巴胺转运体(DAT)、5-羟色胺转运体(SERT)和去甲肾上腺素转运体(NET)的亲和力。SAR 结果表明噻吩(10g)和吡咯(10i)衍生物具有多巴胺去甲肾上腺素再摄取抑制(DNRI)型活性。另一方面,3-羟基苯基衍生物 10f 和 4-甲氧基苯基衍生物 10j 表现出三重再摄取抑制(TUI)活性谱,因为这些分子对所有单胺转运体都表现出强烈的摄取抑制作用(DAT、SERT 和 NET 的 K(i)值分别为 31.3、40、38.5 和 K(i)值分别为 15.9、12.9、29.3)。化合物 10f 进一步在大鼠强迫游泳试验中进行评估,以评估其潜在的抗抑郁作用。结果表明,TUI 10f 在 10mg/kg 剂量下显著减少不动性,表明具有潜在的抗抑郁活性。

相似文献

1
Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.进一步研究 4-((((3S,6S)-6-(苯并[d][1,3]二氧戊环-5-基)四氢-2H-吡喃-3-基)氨基)甲基)苯酚的构效关系:鉴定具有三重摄取抑制活性的化合物作为潜在的抗抑郁药。
J Med Chem. 2011 Apr 28;54(8):2924-32. doi: 10.1021/jm200020a. Epub 2011 Mar 29.
2
Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.三摄取抑制剂4-((((3S,6S)-6-二苯甲基四氢-2H-吡喃-3-基)氨基)甲基)苯酚的柔性和仿生类似物:合成、生物学特性及药效团模型的建立
Bioorg Med Chem. 2014 Jan 1;22(1):311-24. doi: 10.1016/j.bmc.2013.11.017. Epub 2013 Nov 19.
3
Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.(3S,6S)-6-苄基-N-苄基四氢-2H-吡喃-3-胺类似物的结构探索:作为潜在抗抑郁药的强效三单胺再摄取抑制剂的鉴定。
ChemMedChem. 2012 Dec;7(12):2093-100. doi: 10.1002/cmdc.201200352. Epub 2012 Oct 11.
4
The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.新型三取代吡喃衍生物 D-142 具有三重单胺再摄取抑制活性,在啮齿类动物中表现出强大的抗抑郁样活性。
Eur J Pharmacol. 2011 Dec 5;671(1-3):39-44. doi: 10.1016/j.ejphar.2011.09.162. Epub 2011 Sep 24.
5
Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.三取代不对称吡喃衍生物(2S,4R,5R)-2-二苯甲基-5-苄基氨基-四氢吡喃-4-醇及其相应的二取代(3S,6S)吡喃衍生物的进一步结构探索:一种与多巴胺、5-羟色胺和去甲肾上腺素转运体高亲和力相互作用的拟药效团模型。
J Med Chem. 2006 Jul 13;49(14):4239-47. doi: 10.1021/jm0601699.
6
D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.D-161,一种新型的基于吡喃的三重单胺转运体阻滞剂:抗抑郁样作用的行为药理学证据。
Eur J Pharmacol. 2008 Jul 28;589(1-3):73-9. doi: 10.1016/j.ejphar.2008.05.008. Epub 2008 May 20.
7
Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.基于(2S,4R,5R)-2-二苯甲基-5-((4-甲氧基苄基)氨基)四氢-2H-吡喃-4-醇分子模板开发强效多巴胺-去甲肾上腺素摄取抑制剂(DNRIs)。
Bioorg Med Chem. 2015 Feb 15;23(4):821-8. doi: 10.1016/j.bmc.2014.12.040. Epub 2014 Dec 25.
8
Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner.发现新型的(2S,4R,5R)-2-二苯甲基-5-苄基氨基四氢吡喃-4-醇的三取代不对称衍生物,其以立体特异性方式对5-羟色胺和去甲肾上腺素转运体表现出高亲和力。
J Med Chem. 2005 Jul 28;48(15):4962-71. doi: 10.1021/jm049021k.
9
Novel Potent Dopamine-Norepinephrine and Triple Reuptake Uptake Inhibitors Based on Asymmetric Pyran Template and Their Molecular Interactions with Monoamine Transporters.基于不对称吡喃模板的新型强效多巴胺-去甲肾上腺素和三重再摄取抑制剂及其与单胺转运体的分子相互作用。
ACS Chem Neurosci. 2021 Apr 21;12(8):1406-1418. doi: 10.1021/acschemneuro.1c00078. Epub 2021 Apr 12.
10
Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.构象受限三环托烷的联芳基类似物作为强效和选择性去甲肾上腺素再摄取抑制剂:其在单胺转运蛋白位点的摄取抑制作用的合成与评价
J Med Chem. 2003 May 8;46(10):1997-2007. doi: 10.1021/jm020596w.

引用本文的文献

1
Overview of the structure and function of the dopamine transporter and its protein interactions.多巴胺转运体的结构与功能及其蛋白质相互作用概述。
Front Physiol. 2023 Mar 3;14:1150355. doi: 10.3389/fphys.2023.1150355. eCollection 2023.
2
Novel serotonin transporter regulators: Natural aristolane- and nardosinane- types of sesquiterpenoids from Nardostachys chinensis Batal.新型血清素转运体调节剂:来自藏菖蒲的天然aristolane- 和nardosinane- 型倍半萜烯。
Sci Rep. 2017 Nov 8;7(1):15114. doi: 10.1038/s41598-017-15483-6.
3
Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

本文引用的文献

1
Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS).新型三重再摄取抑制剂(1S,2S)-3-(甲氨基)-2-(萘-2-基)-1-苯基丙-1-醇(PRC200-SS)的抗抑郁样药理学特征
J Pharmacol Exp Ther. 2008 Nov;327(2):573-83. doi: 10.1124/jpet.108.143610. Epub 2008 Aug 8.
2
D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.D-161,一种新型的基于吡喃的三重单胺转运体阻滞剂:抗抑郁样作用的行为药理学证据。
Eur J Pharmacol. 2008 Jul 28;589(1-3):73-9. doi: 10.1016/j.ejphar.2008.05.008. Epub 2008 May 20.
3
三重再摄取抑制剂作为潜在的下一代抗抑郁药:新希望?
Future Med Chem. 2015;7(17):2385-406. doi: 10.4155/fmc.15.134. Epub 2015 Nov 30.
4
Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.D-473的药理学和行为学特征,一种口服活性三重再摄取抑制剂,靶向多巴胺、5-羟色胺和去甲肾上腺素转运体。
PLoS One. 2014 Nov 26;9(11):e113420. doi: 10.1371/journal.pone.0113420. eCollection 2014.
5
Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.作为三重再摄取抑制剂的4-杂芳基-1,2,3,4-四氢异喹啉的设计与合成
ACS Med Chem Lett. 2014 May 13;5(7):760-5. doi: 10.1021/ml500053b. eCollection 2014 Jul 10.
6
Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.三摄取抑制剂4-((((3S,6S)-6-二苯甲基四氢-2H-吡喃-3-基)氨基)甲基)苯酚的柔性和仿生类似物:合成、生物学特性及药效团模型的建立
Bioorg Med Chem. 2014 Jan 1;22(1):311-24. doi: 10.1016/j.bmc.2013.11.017. Epub 2013 Nov 19.
7
Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.(3S,6S)-6-苄基-N-苄基四氢-2H-吡喃-3-胺类似物的结构探索:作为潜在抗抑郁药的强效三单胺再摄取抑制剂的鉴定。
ChemMedChem. 2012 Dec;7(12):2093-100. doi: 10.1002/cmdc.201200352. Epub 2012 Oct 11.
8
Novel C-1 substituted cocaine analogs unlike cocaine or benztropine.新型 C-1 取代的可卡因类似物,不同于可卡因或苯环丙胺。
J Pharmacol Exp Ther. 2012 Nov;343(2):413-25. doi: 10.1124/jpet.112.193771. Epub 2012 Aug 15.
Triple reuptake inhibitors ("broad spectrum" antidepressants).
三重再摄取抑制剂(“广谱”抗抑郁药)。
CNS Neurol Disord Drug Targets. 2007 Apr;6(2):141-9. doi: 10.2174/187152707780363285.
4
Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.新型三重再摄取抑制剂PRC025和PRC050的抗抑郁样作用
Eur J Pharmacol. 2007 Jan 19;555(1):30-6. doi: 10.1016/j.ejphar.2006.10.004. Epub 2006 Oct 17.
5
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.DOV 216,303(一种“三重”再摄取抑制剂)的临床前和临床药理学
CNS Drug Rev. 2006 Summer;12(2):123-34. doi: 10.1111/j.1527-3458.2006.00123.x.
6
Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.三取代不对称吡喃衍生物(2S,4R,5R)-2-二苯甲基-5-苄基氨基-四氢吡喃-4-醇及其相应的二取代(3S,6S)吡喃衍生物的进一步结构探索:一种与多巴胺、5-羟色胺和去甲肾上腺素转运体高亲和力相互作用的拟药效团模型。
J Med Chem. 2006 Jul 13;49(14):4239-47. doi: 10.1021/jm0601699.
7
Dopaminergic-based pharmacotherapies for depression.基于多巴胺能的抑郁症药物治疗方法。
Eur Neuropsychopharmacol. 2006 Aug;16(6):391-402. doi: 10.1016/j.euroneuro.2005.12.002. Epub 2006 Jan 18.
8
Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner.发现新型的(2S,4R,5R)-2-二苯甲基-5-苄基氨基四氢吡喃-4-醇的三取代不对称衍生物,其以立体特异性方式对5-羟色胺和去甲肾上腺素转运体表现出高亲和力。
J Med Chem. 2005 Jul 28;48(15):4962-71. doi: 10.1021/jm049021k.
9
Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters.顺式-(6-二苯甲基-哌啶-3-基)-苄胺化合物的2,4-和3,6-二取代吡喃类似物与单胺转运体相互作用的结构要求。
Bioorg Med Chem. 2004 Dec 1;12(23):6301-15. doi: 10.1016/j.bmc.2004.07.069.
10
Further structurally constrained analogues of cis-(6-benzhydrylpiperidin-3-yl)benzylamine with elucidation of bioactive conformation: discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters.顺式-(6-二苯甲基哌啶-3-基)苄胺的进一步结构受限类似物及生物活性构象的阐明:1,4-二氮杂双环[3.3.1]壬烷衍生物的发现及其对单胺转运蛋白的生物学性质评估
J Med Chem. 2004 Oct 7;47(21):5101-13. doi: 10.1021/jm049796t.